NCT05301010 2023-02-27Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer PatientsNanogen Pharmaceutical Biotechnology Joint Stock CompanyPhase 3 Completed128 enrolled